tetano
Editor, Senior Moderator
Antiviral Res
. 2023 Jul 15;105674.
doi: 10.1016/j.antiviral.2023.105674. Online ahead of print. Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable
Yang Li[SUP] 1 [/SUP], Yining Wang[SUP] 1 [/SUP], Yunlong Li[SUP] 1 [/SUP], Annemarie C de Vries[SUP] 1 [/SUP], Pengfei Li[SUP] 1 [/SUP], Maikel P Peppelenbosch[SUP] 1 [/SUP], Qiuwei Pan[SUP] 2 [/SUP]
Affiliations
Seasonal coronaviruses widely circulate in the global population, and severe complications can occur in specific vulnerable populations. Little is known on their pathogenic mechanisms and no approved treatment is available. Here, we present anecdotal evidence that the level of IL-1β, a hallmark of inflammasome activation, appears elevated in a subset of seasonal coronavirus infected patients. We found that cultured human macrophages support the full life cycle of three cultivatable seasonal coronaviruses. Their infections effectively activate NLRP3 inflammasome activation through TLR4 ligation and NF-κB activation. This activation can be attenuated by specific pharmacological inhibitors and clinically used medications including dexamethasone and flufenamic acid. Interestingly, combination of antiviral and anti-inflammatory drugs simultaneously inhibit seasonal coronavirus-triggered inflammatory response and viral replication. Collectively, these findings show that the TLR4/NF-κB/NLRP3 axis drives seasonal coronavirus triggered-inflammatory response, which in turn represents a viable therapeutic target.
Keywords: Combination treatment; NLRP3 inflammasome; Seasonal coronavirus; Therapeutic targeting.
. 2023 Jul 15;105674.
doi: 10.1016/j.antiviral.2023.105674. Online ahead of print. Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable
Yang Li[SUP] 1 [/SUP], Yining Wang[SUP] 1 [/SUP], Yunlong Li[SUP] 1 [/SUP], Annemarie C de Vries[SUP] 1 [/SUP], Pengfei Li[SUP] 1 [/SUP], Maikel P Peppelenbosch[SUP] 1 [/SUP], Qiuwei Pan[SUP] 2 [/SUP]
Affiliations
- PMID: 37459896
- DOI: 10.1016/j.antiviral.2023.105674
Seasonal coronaviruses widely circulate in the global population, and severe complications can occur in specific vulnerable populations. Little is known on their pathogenic mechanisms and no approved treatment is available. Here, we present anecdotal evidence that the level of IL-1β, a hallmark of inflammasome activation, appears elevated in a subset of seasonal coronavirus infected patients. We found that cultured human macrophages support the full life cycle of three cultivatable seasonal coronaviruses. Their infections effectively activate NLRP3 inflammasome activation through TLR4 ligation and NF-κB activation. This activation can be attenuated by specific pharmacological inhibitors and clinically used medications including dexamethasone and flufenamic acid. Interestingly, combination of antiviral and anti-inflammatory drugs simultaneously inhibit seasonal coronavirus-triggered inflammatory response and viral replication. Collectively, these findings show that the TLR4/NF-κB/NLRP3 axis drives seasonal coronavirus triggered-inflammatory response, which in turn represents a viable therapeutic target.
Keywords: Combination treatment; NLRP3 inflammasome; Seasonal coronavirus; Therapeutic targeting.